Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | BRD4 | O60885 | 3/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5440305 | 0.87 | TSHR (0.47) | HSD17B10HPGDKDM4EBRD4EGFR | |
| SCHEMBL5433157 | 0.84 | BRD4 (0.53) | ALDH1A1HPGDBRD4EGFRSMN1; SMN2 | |
| SCHEMBL5423538 | 0.82 | HPGD (0.48) | ALDH1A1HSD17B10HPGDKMT2AKDM4E | |
| SCHEMBL7972454 | 0.80 | EGFR (0.46) | ALDH1A1KMT2AKDM4EBRD4EGFR | |
| SCHEMBL30027960 | 0.79 | EGFR (0.54) | ALDH1A1HSD17B10HPGDKMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL7974150 | 0.77 | BRD4 (0.45) | ALDH1A1KMT2AKDM4EBRD4EGFR | |
| SCHEMBL2473897 | 0.77 | EGFR (0.51) | ALDH1A1HPGDKMT2AKDM4EBRD4 | |
| SCHEMBL7972449 | 0.76 | EGFR (0.45) | ALDH1A1KMT2AKDM4EBRD4EGFR | |
| SCHEMBL5430952 | 0.75 | EGFR (0.50) | ALDH1A1HPGDKMT2AKDM4EBRD4 | |
| SCHEMBL2474259 | 0.74 | EGFR (0.49) | HSD17B10KMT2ABRD4EGFRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032527-A1 | METHOD OF INHIBITING ANGIOGENESIS | HAVIV FORTUNA | 2007-02-08 | — | — | US | claimed |
| EP-1551404-A2 | METHOD OF INHIBITING ANGIOGENESIS | Abbott Laboratories (US) | 2005-07-13 | — | — | EP | claimed |
| US-20040116479-A1 | Method of inhibiting angiogenesis | ABBOTT LABORATORIES | 2004-06-17 | — | — | US | claimed |
| WO-2004032908-A9 | METHOD OF INHIBITING ANGIOGENESIS | ABBOTT LAB (US) | 2004-05-27 | — | — | WO | claimed |
| WO-2004032908-A2 | METHOD OF INHIBITING ANGIOGENESIS | ABBOTT LABORATORIES (US) | 2004-04-22 | — | — | WO | claimed |
| US-20040067985-A1 | Method of inhibiting angiogenesis | ABBOT LABORATORIES | 2004-04-08 | — | — | US | claimed |
| US-20070043089-A1 | METHOD OF INHIBITING ANGIOGENESIS | HAVIV FORTUNA | 2007-02-22 | — | — | US | disclosed |
| US-20070032527-A1 | METHOD OF INHIBITING ANGIOGENESIS | HAVIV FORTUNA | 2007-02-08 | — | — | US | disclosed |
| US-20040116479-A1 | Method of inhibiting angiogenesis | ABBOTT LABORATORIES | 2004-06-17 | — | — | US | disclosed |
| WO-2004032908-A9 | METHOD OF INHIBITING ANGIOGENESIS | ABBOTT LAB (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040067985-A1 | Method of inhibiting angiogenesis | ABBOT LABORATORIES | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032527-A1 | METHOD OF INHIBITING ANGIOGENESIS | PGF, VEGFA, FLT4 | ALDH1A1 837/4885HSD17B10 904/4885HPGD 158/4885 |
| US-20070043089-A1 | METHOD OF INHIBITING ANGIOGENESIS | PGF, VEGFA, FLT4 | ALDH1A1 837/4885HSD17B10 904/4885HPGD 158/4885 |
| US-20040067985-A1 | Method of inhibiting angiogenesis | VEGFA, PGF, FLT4 | ALDH1A1 450/4885HSD17B10 617/4885HPGD 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.